Journal of Neural Transmission

, Volume 121, Issue 10, pp 1281–1286 | Cite as

Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson’s disease and in hepatic encephalopathy

  • Mariacristina Siotto
  • Patrizio Pasqualetti
  • Massimo Marano
  • Rosanna Squitti
Neurology and Preclinical Neurological Studies - Original Article


Ceruloplasmin (Cp) is a serum ferroxidase that plays an essential role in iron metabolism. It is routinely tested by immunoturbidimetric assays that quantify the concentration of the protein both in its active and inactive forms. Cp activity is generally analyzed manually; the process is time-consuming, has a limited repeatability, and is not suitable for a clinical setting. To overcome these inconveniences, we have set the automation of the o-dianisidine Cp activity assay on a Cobas Mira Plus apparatus. The automation was rapid and repeatable, and the data were provided in terms of IU/L. The assay was adapted for human sera and showed a good precision [coefficient of variation (CV) 3.7 %] and low limit of detection (LoD 11.58 IU/L). The simultaneous analysis of Cp concentration and activity in the same run allowed us to calculate the Cp-specific activity that provides a better index of the overall Cp status. To test the usefulness of this automation, we tested this assay on 104 healthy volunteers and 36 patients with Wilson’s disease, hepatic encephalopathy, and chronic liver disease. Cp activity and specific activity distinguished better patients between groups with respect to Cp concentration alone, and providing support for the clinical investigation of neurological diseases in which liver failure is one of the clinical hallmarks.


Ceruloplasmin Ceruloplasmin activity Wilson’s disease Hepatic diseases Neurodegenerative diseases Hepatic encephalopathy 





Enzymatic Cp


Immunologic Cp


Healthy volunteers


Wilson’s disease


Chronic liver disease


Hepatic encephalopathy


Hepatitis C virus


Coefficient of variation


Limit of detection


Limit of blank



The authors thank Dr.Vernieri F., Dr. Altamura, C. (Department of Neurology) and Dr. Vespasiani Gentilucci U., Dr. Picardi A. (Department of Clinical Medicine and Hepatology) of University Campus Bio-Medico of Rome, Italy, for providing the samples. This study was partially supported by the Grant: Italian Health Department: “Profilo Biologico e Genetico della Disfunzione dei Metalli nella Malattia di Alzheimer e nel ‘Mild Cognitive Impairment” [RF 2006 conv.58].


  1. Altamura C, Squitti R, Pasqualetti P, Gaudino C, Palazzo P, Tibuzzi F, Lupoi D, Cortesi M, Rossini PM, Vernieri F (2009) Ceruloplasmin/Transferrin system is related to clinical status in acute stroke. Stroke 40:1282–1288PubMedCrossRefGoogle Scholar
  2. Armbruster DA, Pry T (2008) Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29(Suppl 1):S49–S52PubMedPubMedCentralGoogle Scholar
  3. Bielli P, Calabrese L (2002) Structure to function relationships in ceruloplasmin: a ‘moonlighting’ protein. Cell Mol Life Sci 59:1413–1427PubMedCrossRefGoogle Scholar
  4. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C (2008) Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33:1717–1723PubMedCrossRefGoogle Scholar
  5. Boyett JD, Lehmann HP, Beeler MF (1976) Automated assay of ceruloplasmin by kinetic analysis of o-dianisidine oxidation. Clin Chim Acta 69:233–241PubMedCrossRefGoogle Scholar
  6. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R (2010) Copper and ceruloplasmin abnormalities in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 25:490–497PubMedCrossRefGoogle Scholar
  7. Burtis CA, Ashwood ER, Bruns DE (2012) Tietz textbook of clinical chemistry and molecular diagnostics. Elsevier, NetherlandsGoogle Scholar
  8. Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, Calabrese L, Rossi L (2008) Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer’s disease patients. Biometals 21:367–372PubMedCrossRefGoogle Scholar
  9. Endo F, Taketa K, Nakamura K, Awata H, Tanoue A, Eda Y, Matsuda I (1994) Measurement of blood holoceruloplasmin by EIA using a mouse monoclonal antibody directed to holoceruloplasmin. Implication for mass screening of Wilson disease. J Inherit Metab Dis 17:616–620PubMedCrossRefGoogle Scholar
  10. Erel O (1998) Automated measurement of serum ferroxidase activity. Clin Chem 44:2313–2319PubMedGoogle Scholar
  11. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei A (2002) Hepatic encephalopathy––definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35(3):716–721PubMedCrossRefGoogle Scholar
  12. Gutteridge JM (1995) Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 41:1819–1828PubMedGoogle Scholar
  13. Healy J, Tipton K (2007) Ceruloplasmin and what it might do. J Neural Transm 114:777–781PubMedCrossRefGoogle Scholar
  14. Hellman NE, Gitlin JD (2002) Ceruloplasmin metabolism and function. Annu Rev Nutr 22:439–458PubMedCrossRefGoogle Scholar
  15. Hiyamuta S, Shimizu K, Aoki T (1993) Early diagnosis of Wilson disease. Lancet 342:56–57PubMedCrossRefGoogle Scholar
  16. Kozlov AV, Sergienko VI, Vladimirov IuA, Azizova OA (1984) The antioxidant system of transferrin-ceruloplasmin in experimental hypercholesterolemia. Biull Eksp Biol Med 98:668–671PubMedGoogle Scholar
  17. Kristinsson J, Snaedal J, Tórsdóttir G, Jóhannesson T (2012) Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: a synopsis of recent studies. Neuropsychiatr Dis Treat 8:515–521PubMedPubMedCentralGoogle Scholar
  18. Lehmann HP, Schosinsky KH, Beeler MF (1974) Standardization of serum ceruloplasmin concentrations in international enzyme units with o-dianisidine dihydrochloride as substrate. Clin Chem 20:1564–1567PubMedGoogle Scholar
  19. Linnet K, Kondratovich M (2004) Partly nonparametric approach for determining the limit of detection. Clin Chem 50:732–740PubMedCrossRefGoogle Scholar
  20. Macintyre G, Gutfreund KS, Martin WR, Camicioli R, Cox DW (2004) Value of an enzymatic assay for the determination of serum ceruloplasmin. J Lab Clin Med 144:294–301PubMedCrossRefGoogle Scholar
  21. Martinez-Subiela S, Tecles F, Ceron JJ (2007) Comparison of two automated spectrophotometric methods for ceruloplasmin measurement in pigs. Res Vet Sci 83:12–19PubMedCrossRefGoogle Scholar
  22. Merle U, Eisenbach C, Weiss KH, Tuma S, Stremmel W (2009) Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson’s disease. J Hepatol 51:925–930PubMedCrossRefGoogle Scholar
  23. Milne DB, Johnson PE (1993) Assessment of copper status: effect of age and gender on reference ranges in healthy adults. Clin Chem 39:883–887PubMedGoogle Scholar
  24. Osaki S, Johnson DA (1969) Mobilization of liver iron by ferroxidase (ceruloplasmin). J Biol Chem 244:5757–5758PubMedGoogle Scholar
  25. Scheinberg IH, Sternlieb I (1965) Wilson’s disease. Annu Rev Med 16:119–134PubMedCrossRefGoogle Scholar
  26. Schosinsky KH, Lehmann HP, Beeler MF (1974) Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 20:1556–1563PubMedGoogle Scholar
  27. Sunderman FW Jr, Nomoto S (1970) Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chem 16:903–910PubMedGoogle Scholar
  28. Torsdottir G, Kristinsson J, Snaedal J, Jóhannesson T (2011) Ceruloplasmin and iron proteins in the serum of patients with Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 1(1):366–371PubMedCrossRefPubMedCentralGoogle Scholar
  29. Vassiliev V, Harris ZL, Zatta P (2005) Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 49:633–640PubMedCrossRefGoogle Scholar
  30. Walshe JM (2003) Wilson’s disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 40:115–121PubMedCrossRefGoogle Scholar
  31. Wolf PL (1982) Ceruloplasmin: methods and clinical use. Crit Rev Clin Lab Sci 17:229–245PubMedCrossRefGoogle Scholar
  32. Zegers I, Beetham R, Keller T, Sheldon J, Bullock D, Mackenzie F, Trapmann S, Emons H, Schimmel H (2013) The importance of commutability of reference materials used as calibrators: the example of ceruloplasmin. Clin Chem 59:1322–1329PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2014

Authors and Affiliations

  • Mariacristina Siotto
    • 1
  • Patrizio Pasqualetti
    • 2
    • 3
  • Massimo Marano
    • 4
  • Rosanna Squitti
    • 5
    • 6
  1. 1.Don Carlo Gnocchi Foundation ONLUSMilanItaly
  2. 2.Medical Statistics and Information Technology, Fatebenefratelli Foundation for Health Research and Education, AFaR DivisionRomeItaly
  3. 3.Unit of Clinical and Molecular EpidemiologyIRCCS “San Raffaele Pisana”RomeItaly
  4. 4.Department of NeurologyUniversity “Campus Bio-medico”RomeItaly
  5. 5.Fatebenefratelli Foundation for Health Research and Education, AFaR DivisionRomeItaly
  6. 6.Laboratorio di NeurodegenerazioneIRCCS “San Raffaele Pisana”RomeItaly

Personalised recommendations